您所在的位置: 首页 >>English >>Academic Trends >>Academic Exchanges >> 正文

English

Academic Exchanges

EHA News
4 Research Achievements Unveiled at The Global Hematology Event, New Hope for Patients with Hematological Malignancies

字号: + - 14

On June 13-16, the 24th Conference of the European Hematology Association (EHA 2019) is being held in Amsterdam, the Netherlands. This event is hosted by the European Hematology Association (EHA), and as the largest international conference in the field of hematology in Europe, it attracts more than 10,000 professionals from more than 100 countries around the world. The world's most advanced research progresses and clinical experience can finally appear at the EHA after strict selection and screening, and being on the EHA stage represents the higher academic level in the field of hematology. This time, Beijing Boren Hospital of Gaobo Healthcare Group has 4 scientific research achievements exhibited on the conference poster to show and share Boren's scientific research achievements and clinical practice experience with the world.

Jing PAN: Two CAR-T studies appear at EHA, which brings hope to patients with relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL)

A true case of American patient with leukemia Emily who was cured with the help of CAR-T therapy inspires the patients and hematologists around the world, and CAR-T therapy has become a star therapy for hematological malignancies. Initially, CD19-CAR-T therapy showed good efficacy in the treatment of refractory and relapsed B-ALL. But in foreign countries, the long-term observation of CD19-CAR-T therapy in the treatment of B-ALL showed that the 5-year relapse-free survival rate was only about 20%. The research team led by Director Chunrong TONG has early noticed the relapse after CD19-CAR-T therapy. Through years of research and innovation, the team is trying to solve this thorny problem, and Dr. Jing PAN is one of the doctors who have made the most prominent achievements in clinical practice and research. At this EHA conference, Dr. Jing PAN's two achievements on CAR-T therapy are presented in the poster. The study "Sequential CD19 and CD22 CAR-T therapies for 11 children with refractory and relapsed B-ALL" found that sequential CD19- and CD22-CAR-T cell therapies were relatively safe in patients with refractory/relapsed B-ALL who could not undergo bridging allogeneic hematopoietic stem cell transplantation (allo-HCT). The adopted sequential CAR-T cell therapy could improve the 1-year leukemia-free survival rate of the patients (67.9%).

14.jpg

Poster of Dr. Jing PAN

Another study that Dr. Jing PAN brought to the EHA is “CD22-CAR-T Cell Therapy for 34 Cases of Refractory/Relapsed B-cell Acute Lymphoblastic Leukemia (B-ALL)”, which suggests that currently for children with B-ALL who have no response to CD19-CAR-T cell therapy, CD22-CAR-T cell therapy can be a very effective treatment, and it has low-grade, low-incidence, monitorable and controllable CRS levels and provides a valuable window for achieving persistent remission after subsequent transplantation.

Dr. Jing PAN, on behalf of the research team, contributed this study to the Leukemia (SCI10.023) for inclusion and publication. This is the first time that the Chinese team's achievement on CD22-CAR-T therapy for refractory and relapsed B-ALL is published in the international journal, and it is also the second clinical study published globally in this field. This is the research team led by Director Chunrong TONG that published academic achievements in the Leukemia twice in two years. Dr. Jing PAN is the first author of this selected paper, and Director Chunrong TONG is the corresponding author.

未标题-4.jpg

Poster of Dr. Jing PAN

image.png

Dr. Jing PAN at the EHA conference

Zhihui LI: To explore the potential effects of blood and immune-related genetic susceptibility genes carried by patients on the results of allogeneic hematopoietic stem cell transplantation

The poster report brought by Dr. Zhihui LI is "IDENTIFYING RELATIONSHIP BETWEEN HEREDITARY PREDISPOSITION GENE AND COMPLICATIONS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACUTE LEUKEMIA".

As a main treatment for hematological malignancies, the success of hematopoietic stem cell transplantation is related to many factors. The preliminary research conducted by Dr. Zhihui LI found that blood and immune-related genetic susceptibility genes carried by patients had a certain correlation with infections, graft-versus-host disease (GVHD), relapse and other major complications occurring after allogeneic hematopoietic stem cell transplantation. For example, the incidence and severity of GVHD after transplantation in patients carrying hemophagocytic lymphohistiocytosis (HLH) gene were significantly higher than those in patients not carrying HLH gene; the incidence of infection after transplantation in patients carrying Fanconi anemia gene was higher than that in patient not carrying this gene. The results of this study provide a reference for the selection and adjustment of the treatment regimen of hematopoietic stem cell transplantation. Therefore, detection of blood and immune-related genetic susceptibility genes before transplantation is important for the early prevention and treatment of complications after transplantation and improve the success rate of transplantation. The team represented by Dr. Zhihui LI exhibited the achievement at the conference.

The effects of blood and immune-related genetic susceptibility genes on the occurrence of hematological malignancies, treatment response and prognosis and the results of transplantation need to be further studied and explored, and it is worthy of further conducting deeper and meticulous researches.

15.jpg

Poster of Dr. Zhihui LI

image.png

Dr. Zhihui LI at the EHA Conference

Wenqun ZHANG: CAR-T therapy for refractory and relapsed Burkitt's lymphoma, a new idea for the treatment of pediatric lymphoma

The poster report brought by Dr. Wenqun ZHANG is "Chimeric antigen receptor T-cells (CAR-T) for refractory and relapsed Burkitt's lymphoma: early response in pediatric patients”

Burkitt's lymphoma (BL) is a highly invasive B-cell lymphoma that is highly prevalent in children, and it is the most common pathological type of non-Hodgkin's lymphoma in children. The clinical team led by Professor Yonghong ZHANG used a high-intensity and short-course chemotherapy regimen to treat BL and achieved good efficacy, especially use of rituximab achieved a 5-year event-free survival rate up to 80% in high-risk patients. However, 10%-15% of patients with Burkitt's lymphoma had no response to chemotherapy. Once the intensity of chemotherapy was weak or the chemotherapy was delayed, the tumor cells would rapidly develop drug resistance, and the patients would have no response to chemotherapy again, be difficult to achieve remission again and lose the possibility of cure. In such cases, the effective rate of second-line chemotherapy was less than 10%, and the survival rate of tumor-bearing transplantation was 0. In previous similar cases, treatment could only be given up. In the face of the urgent problems, experts continue to explore new solutions.

Professor Yonghong ZHANG said that the success of CAR-T in the treatment of refractory and relapsed leukemia is a great encouragement to clinicians, then there is another report on the success of CAR-T in the treatment of adult diffuse large B-cell lymphoma, and the data of several clinical trials have demonstrated that CAR-T cells can treat various subtypes of B-cell lymphomas, including follicular lymphoma, mantle cell lymphoma and marginal zone lymphoma, but no report of CAR-T in the treatment of Burkitt's lymphoma has been available before.

The Pediatric Lymphoma Team in Beijing Boren Hospital has first created the sequential CD19/CD20/CD22-CAR-T therapy for refractory and relapsed Burkitt's lymphoma in children, which is a breakthrough innovation in the field of pediatric lymphoma and is a new idea in the treatment of Burkitt's lymphoma. It is more noteworthy that this study has shown a strong therapeutic effect. The CAR-T response rate in 5 children with Burkitt's lymphoma in this study was up to 100%, and even in the relatively mature treatment of leukemia with CAR-T, the response rate of 100% is also relatively rare. Moreover, we also noted that the relevant toxic reactions of sequential CAR-T in this study were moderate and controllable.

The results of this study, for children with refractory and relapsed Burkitt's lymphoma who have no response to chemotherapy, are tantamount to a ray of light in the dark night, rekindling the hope of life, and have profound significance for clinicians or patients and families.

未标题-6.jpg

Poster of Dr. Wenqun ZHANG:

Dr. Wenqun ZHANG, on behalf of the team, exhibited the achievements at the conference, and it was learned that this study won the opportunity of an oral presentation at the 15th International Conference of Malignant Lymphomas held in Lugano, Switzerland, to show the China strength to the global field of lymphoma.

Scientific research and innovation is not easy, and continuous innovation is even more commendable. Private medical institutions have an arduous and long way of academic research. Beijing Boren Hospital today has never missed the world's top academic conferences on hematology. And from the emergence of one study to the ongoing four studies unveiled at EHA 2019, it uses strength and achievements to give patients a bright future.